Effects of Drugs on Bone Quality

被引:7
作者
Imbert L. [1 ]
Boskey A. [1 ]
机构
[1] Musculoskeletal Integrity Program, Hospital for Special Surgery Research Institute, 535 E 70th St, New York, 10021, NY
来源
Clinical Reviews in Bone and Mineral Metabolism | 2016年 / 14卷 / 3期
基金
美国国家卫生研究院;
关键词
Bisphosphonates; Bone quality; Drugs; Osteoporosis; Secondary osteoporosis; Treatment;
D O I
10.1007/s12018-016-9220-6
中图分类号
学科分类号
摘要
The term bone quality refers to factors that define bone mechanical strength and hence its fracture risk, either inclusive or exclusive of the quantity of mineralized tissue present. These factors include: bone size, density, shape (microarchitecture, geometry, remodeling cavity number size and distribution), porosity, mineral and collagen distribution and alignment, amount and distribution of microdamage, mineral composition, collagen cross-linking and other material properties. In this review, we will consider how pharmaceuticals used to treat osteoporosis (anabolic and catabolic agents) and those used for other conditions that affect bone quality and induce “secondary osteoporosis” alter these parameters. Observed effects vary with different methods of drug delivery, length and periodicity of use, other drugs used concomitantly or consecutively, user gender, methods of analysis and, most importantly, the genetic background of the species tested. We suggest that while increases in quantity of mineralized tissue present account for much of the reported reduction in fracture risk, drugs that correct the composition and microarchitecture of the bone, returning it to its preosteoporotic status, may provide additional benefits. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:167 / 196
页数:29
相关论文
共 161 条
  • [1] Hernandez C.J., Keaveny T.M., A biomechanical perspective on bone quality, Bone, 39, pp. 1173-1181, (2006)
  • [2] Fyhrie D.P., Summary-Measuring “bone quality, J Musculoskelet Neuronal Interact, 5, pp. 318-320, (2005)
  • [3] Burr D.B., Bone biomechanics and bone quality: effects of pharmaceutical agents used to treat osteoporosis, Clinic Rev Bone Miner Metab, (2016)
  • [4] Hunt H.B., Donnelly E., Bone quality assessment techniques: geometric, compositional, and mechanical characterization from macroscale to nanoscale, Clinic Rev Bone Miner Metab, (2016)
  • [5] Aref M.W., McNerny E.M.B., Brown D., Jepsen K.J., Allen M.R., Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes, Osteoporos Int, (2016)
  • [6] Wen X.X., Wang F.Q., Xu C., Et al., Time related changes of mineral and collagen and their roles in cortical bone mechanics of ovariectomized rabbits, PLoS One, 10, (2015)
  • [7] Boskey A.L., Marino J., Spevak L., Et al., Are changes in composition in response to treatment of a mouse model of osteogenesis imperfecta sex-dependent?, Clin Orthop Relat Res, 473, pp. 2587-2598, (2015)
  • [8] Paschalis E.P., Fratzl P., Gamsjaeger S., Et al., Aging versus postmenopausal osteoporosis: bone composition and maturation kinetics at actively-forming trabecular surfaces of female subjects aged 1 to 84 Years, J Bone Miner Res, 31, pp. 347-357, (2016)
  • [9] Tong X., Burton I.S., Isaksson H., Et al., Cortical bone histomorphometry in male femoral neck: the investigation of age-association and regional differences, Calcif Tissue Int, 96, pp. 295-306, (2015)
  • [10] Makowski A.J., Uppuganti S., Wadeer S.A., Et al., The loss of activating transcription factor 4 (ATF4) reduces bone toughness and fracture toughness, Bone, 62, pp. 1-9, (2014)